The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
The FDA has approved IntraBio's Aqneursa, an orally administered modified amino acid known as levacetylleucine, to treat neurological symptoms in patients with ataxia-telangiectasia.
Roche will pay Dualitas Therapeutics $36.5 million upfront to test more than 300,000 bispecific antibody pairings across immunology and inflammation targets.
Novo Nordisk has agreed to a collaboration worth up to $1.4 billion with Orbis Medicines to develop oral macrocyclic peptides for cardiometabolic diseases.
SK Biopharmaceuticals will pay 1ST Biotherapeutics $1.8 million upfront, with total milestone potential bringing the headline deal value to $314.8 million, or roughly $315 million, for 1ST-104, an oral dual inhibitor of LRRK2 and c-Abl.
Novo Nordisk has partnered with AI startup Anthropic to deploy its Claude model across early drug discovery and research operations.
GenomeFrontier Therapeutics will adapt the production of GF-CART01, an autologous virus-free CAR T-cell therapy, to run on Cellares' automated Cell Shuttle system.
Novo Nordisk plans to deploy Anthropic's Claude Science model to assist with scientific reasoning across drug research and development and agentic software tasks.
Cell therapy bioprocessing specialist Ori Biotech has agreed to a $120 million contract to implement its automated production platform for an undisclosed commercial-stage cell therapy.
The Mayo Clinic and Thermo Fisher Scientific have launched Precure LLC, a joint venture built to assemble large-scale datasets combining genomic, proteomic, and longitudinal clinical records.
GSK has agreed to pay up to $750 million in a licensing deal for Chimagen Biosciences' preclinical trispecific T-cell engager, with plans to begin Phase 1 trials in multiple myeloma next year.
Eli Lilly entered a multi-program research partnership with Toronto-based QurCan Therapeutics, offering an upfront payment, equity investment, and up to $237 million in milestones per program to deliver genetic medicines across the blood-brain barrier.